Vanguard Group Inc Rezolute, Inc. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

A detailed history of Vanguard Group Inc transactions in Rezolute, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,932,057 shares of RZLT stock, worth $9.85 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,932,057

Previous 1,618,036 19.41%

Holding current value

$9.85 Million

Previous $6.96 Million 34.68%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$4.13 - $5.31 $1.3 Million - $1.67 Million	314,021 Added 19.41%	1,932,057 $9.37 Million
Q2 2024 Aug 13, 2024	BUY	$2.29 - $5.79 $148,126 - $374,520	64,684 Added 4.16%	1,618,036 $6.96 Million
Q1 2024 May 10, 2024	BUY	$0.95 - $2.55 $138,415 - $371,535	145,700 Added 10.35%	1,553,352 $3.96 Million
Q4 2022 Feb 10, 2023	BUY	$1.38 - $2.84 $764 - $1,573	554 Added 0.04%	1,407,652 $2.91 Million
Q3 2022 Nov 14, 2022	SELL	$2.19 - $3.49 $72 - $115	-33 Reduced -0.0%	1,407,098 $3.86 Million
Q2 2022 Aug 12, 2022	BUY	$2.6 - $3.85 $2.76 Million - $4.09 Million	1,063,392 Added 309.36%	1,407,131 $4.55 Million
Q1 2022 May 13, 2022	BUY	$2.27 - $5.1 $23,835 - $53,549	10,500 Added 3.15%	343,739 $1.16 Million
Q4 2021 Feb 14, 2022	BUY	$4.21 - $7.61 $845,671 - $1.53 Million	200,872 Added 151.75%	333,239 $1.59 Million
Q3 2021 Nov 12, 2021	BUY	$7.45 - $13.66 $767,178 - $1.41 Million	102,977 Added 350.38%	132,367 $990,000
Q2 2021 Aug 13, 2021	BUY	$6.11 - $15.99 $179,572 - $469,946	29,390 New	29,390 $419,000

Others Institutions Holding RZLT

# of Institutions

Shares Held

38.5M

Call Options Held

1.6K

Put Options Held

24.6K

View Full List

About Rezolute, Inc.

Ticker RZLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,600
Market Cap $198M
Description
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...

More about RZLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Rezolute, Inc. Transaction History